Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effects and Safety of Pantoprazole for Children and Teens with Healed Erosive Esophagitis

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called pantoprazole in children and teenagers who have a condition known as erosive esophagitis. Erosive esophagitis is a condition where the lining of the esophagus, the tube that carries food from the mouth to the stomach, becomes inflamed and damaged. The purpose of the study is to explore how well pantoprazole can maintain the healing of this condition in participants aged 1 to 17 years.

Participants in the study will receive pantoprazole in the form of a capsule, which they will take by mouth. The study will compare two different doses of pantoprazole to see which is more effective and safe for maintaining the healing of erosive esophagitis. Some participants may receive a placebo, which looks like the medication but does not contain the active ingredient. The study will last for up to 24 weeks, during which time participants will have regular check-ups to monitor their health and the condition of their esophagus.

The study will assess the safety and tolerability of pantoprazole by conducting physical examinations and monitoring any side effects. Participants will also have their blood pressure and pulse rate checked, and laboratory tests will be performed to ensure their well-being. The main goal is to confirm that the healing of erosive esophagitis is maintained over the course of the study. This research aims to provide valuable information on the use of pantoprazole in young patients with this condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Enrollment

    Upon joining the study, you will be enrolled after confirming the presence of an erosive lesion in your esophagus. This is done through a procedure called an endoscopy, which involves using a small camera to look inside your esophagus.

    If you have already had an endoscopy within the last 12 weeks that confirmed the lesion, you may not need another one immediately. If you have not, an initial endoscopy will be performed to confirm the lesion.

  2. Step 2

    Healing phase

    If you have not completed at least 8 weeks of healing therapy with a proton pump inhibitor (PPI), you will continue this treatment. A PPI is a type of medication that reduces stomach acid, helping to heal the esophagus.

    If you are already taking pantoprazole, you will continue with the same dosage. If you are taking a different PPI, it must be approved for use in children and taken according to local guidelines.

  3. Step 3

    Confirmation of healing

    At the end of the 8-week healing phase, a follow-up endoscopy will be performed to confirm that the lesion in your esophagus has healed.

    This step is necessary to ensure that the treatment has been effective before moving on to the next phase of the study.

  4. Step 4

    Maintenance phase

    Once healing is confirmed, you will enter the maintenance phase of the study. This phase involves taking the study medication, pantoprazole, in capsule form.

    The dosage and frequency of the medication will be determined by the study protocol and will be explained to you by the study team.

  5. Step 5

    Monitoring and assessments

    Throughout the study, your health will be monitored through regular physical examinations, laboratory tests, and assessments of your blood pressure and pulse rate.

    You will also be asked to complete an electronic diary to record any symptoms or side effects you experience, as well as your use of the study medication and any rescue medications.

  6. Step 6

    End of study

    The primary goal of the study is to confirm the maintenance of healing of erosive esophagitis at week 24.

    At the end of the study, a final assessment will be conducted to evaluate the outcomes and ensure your safety.

Who can join the trial?

8 criteria

  • Participants must have a documented erosive lesion in the esophagus, which is a sore or damage in the tube that connects the mouth to the stomach. This must be confirmed by a procedure called an EGD (a test where a doctor looks inside the esophagus with a camera).
  • If the participant has already started treatment with a PPI (a type of medicine that reduces stomach acid) to heal the lesion, they must continue this treatment for up to 8 weeks.
  • Participants must be able to give signed informed consent or assent, which means they agree to follow the study rules and understand what the study involves.
  • The participant or their parent/legal guardian must be willing and able to complete an electronic diary and other study-related logs and questionnaires throughout the study.
  • Participants must be willing and able to attend all scheduled visits, follow the treatment plan, and complete all tests and procedures required by the study.
  • Participants must be between the ages of 1 and 17 years.
  • Participants must weigh at least 7 kg (about 15 pounds).
  • Both male and female participants can join the study. Females who can have children must follow specific study rules, and those who cannot have children must meet certain criteria.

Who cannot join the trial?

8 criteria

  • Participants with any other serious health conditions that might interfere with the study.
  • Participants who are currently taking medications that could affect the study results.
  • Participants who have had surgery on their esophagus or stomach.
  • Participants with a history of drug or alcohol abuse.
  • Participants who are pregnant or breastfeeding.
  • Participants who have participated in another clinical trial recently.
  • Participants with known allergies to the study medication.
  • Participants who are unable to follow the study procedures.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Pantoprazole is a medication used in this clinical trial to help maintain the healing of erosive esophagitis in children and teenagers. Erosive esophagitis is a condition where the lining of the esophagus becomes inflamed and damaged due to stomach acid. Pantoprazole works by reducing the amount of acid produced in the stomach, which helps prevent further damage to the esophagus and allows it to heal. This medication is taken orally, meaning it is swallowed in the form of a pill or liquid. The trial is exploring how well pantoprazole works in keeping the esophagus healed in young participants who have already experienced healing from previous treatment.

What is already known about the treatment

Pantoprazole – Pantoprazole is administered orally in the form of tablets or granules and is used to maintain the healing of erosive esophagitis, a condition where the lining of the esophagus is eroded due to stomach acid. It is currently being studied in clinical trials to assess its effectiveness and safety in children aged 1 to 17 years. The medication works by reducing the amount of acid produced in the stomach, helping to prevent further damage to the esophagus. Pantoprazole belongs to a class of drugs known as proton pump inhibitors, which are commonly used to treat acid-related stomach and esophagus problems.

Investigated diseases

Erosive Esophagitis – Erosive esophagitis is a condition characterized by inflammation and damage to the lining of the esophagus, often caused by stomach acid reflux. This damage can lead to the formation of erosions or ulcers in the esophageal lining. The progression of the disease involves the worsening of these erosions, which can cause symptoms such as heartburn, difficulty swallowing, and chest pain. Over time, repeated exposure to stomach acid can lead to more severe damage and complications. The condition can fluctuate, with periods of healing and recurrence. It is important to manage the underlying causes to prevent further esophageal damage.
Trial detailsLast updated 7 Oct 2026
Age0-17PhasePhase IITrial ID2023-508770-28-00Protocol codeB1791094Estimated enrolment126 patientsSponsorPfizer Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.